(Q37779489)

23 August 2017

1 reference

title

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies (English)

1 reference

23 August 2017

4

L Willems

1 reference

23 August 2017

N Chapuis

1

1 reference

23 August 2017

J Tamburini

2

1 reference

23 August 2017

A S Green

3

1 reference

23 August 2017

V Bardet

5

1 reference

23 August 2017

S Park

6

1 reference

23 August 2017

C Lacombe

7

1 reference

23 August 2017

P Mayeux

8

1 reference

23 August 2017

D Bouscary

9

1 reference

23 August 2017

publication date

12 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1686-1699

1 reference

Sourcing a chemical succession for cyclosporin from parasites and human pathogens

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Tor signalling in bugs, brain and brawn

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Regulation of TORC1 by Rag GTPases in nutrient response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Bidirectional transport of amino acids regulates mTOR and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Regulation of PTEN transcription by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The TSC1-TSC2 complex is required for proper activation of mTOR complex 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Autophagy and signaling: their role in cell survival and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

An emerging role of mTOR in lipid biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A critical role for Lyn in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

7 January 2021

mTOR inhibitors in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

7 January 2021

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

7 January 2021

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.170

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.170

1 reference

23 August 2017

1 reference